[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341679-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341679-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","incidence-and-survival-of-primary-metastatic-breast-cancer-in-denmark-implication-of-breast-cancer-screening-classification-and-staging-practice-study-results-and-findings","Incidence and survival of primary metastatic breast cancer in Denmark - implication of breast cancer screening, classification, and staging practice - study results and findings","","Primary metastatic breast cancer (pMBC) represents 5–10% of annual cases and carries a median survival of 3–4 years, varying by subtype. This retrospective observational study evaluates pMBC diagnosed between 2000 and 2020 across all Danish oncology departments using Danish Breast Cancer Group and National Patient Register data. Results show 3,272 patients, increasing diagnoses over time, changes in workup intensity, and improved overall survival, while stage migration and registration changes limit causal inference.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/incidence-and-survival-of-primary-metastatic-breast-cancer-in-denmark-implication-of-breast-cancer-screening-classification-and-staging-practice-study-results-and-findings/341679/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/incidence-and-survival-of-primary-metastatic-breast-cancer-in-denmark-implication-of-breast-cancer-screening-classification-and-staging-practice-study-results-and-findings/341679.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study design and study period for primary metastatic breast cancer in Denmark?","Question",{"text":63,"@type":64},"The study is a retrospective observational analysis of pMBC patients diagnosed between 2000 and 2020, including cases from all Danish oncology departments.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the number of primary metastatic breast cancer diagnoses change over time?",{"text":68,"@type":64},"From 2000–2004 to 2015–2020, diagnoses increased from 355 to 1,323, totaling 3,272 patients during 2000–2020.",{"name":70,"@type":61,"acceptedAnswer":71},"What trends were found in survival and diagnostic/staging practices?",{"text":72,"@type":64},"Overall survival improved from 23 months (2000–2004) to 33 months (2015–2020), while diagnostic practices evolved, with a larger proportion evaluated using PET/CT or CT with bone evaluation by 2015–2020 compared with 2000–2004.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341679,1790118622,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","ORIGINAL ARTICLE  \nIncidence and survival of primary metastatic breast cancer in Denmark: implication of breast cancer screening, classification, and staging practice  \nTobias Berga,b, Maj-Britt Jensena, Maria Rossingc,d, Christian T. Axelsene, Iben Kümlerf, Lise Søndergaardg, Marianne Vogsenh,i, Ann S. Knoopa,b and Bent Ejlertsena,b,d  \na Danish Breast Cancer Group, Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Denmark; bDepartment of Oncology, Copenhagen University Hospital, Rigshospitalet, Denmark; cCenter for Genomic Medicine, Copenhagen University Hospital, Rigshospitalet, Denmark; dDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; e Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; fDepartment of Oncology, Copenhagen University Hospital, Herlev Hospital, Herlev, Denmark; gDepartment of Oncology, Zealand University Hospital, Næstved Sygehus, Denmark; hDepartment of Oncology, Odense University Hospital, Odense, Denmark; iDepartment of Clinical Research, University of Southern Denmark, Odense, Denmark  \nABSTRACT  \nBackground: Primary metastatic breast cancer (pMBC) accounts for 5–10% of annual breast cancers with a median survival of 3–4 years, varying among subtypes. In Denmark, the incidence of breast cancer increased until 2010, followed by a stabilisation. Several factors influencing pMBC incidence and survival, including screening prevalence, staging methods, and classification standards, remain pivotal but inadequately documented.  \nMaterial and method: This retrospective observational study involving pMBC patients diagnosed between 2000 and 2020 encompassed all Danish oncology departments. Data from the Danish Breast Cancer Group database and the National Patient Register included diagnosis specifics, demographics, treatment, and follow-up.  \nResults: Between 2000 and 2020, 3,272 patients were diagnosed with pMBC, a rise from 355 patients in 2000–2004 to 1,323 patients in 2015–2020. The increase was particularly observed in patients aged 70 years or older. Changes in tumour subtypes were observed, notably with a rise in human epidermal growth factor receptor 2 (HER2)-positive cases but a steady distribution of estrogen receptor (ER) status. Diagnostic practices changed over the two decades, with 6% evaluated with PET/CT (positron emission tomography– computed tomography) or CT (computed tomography) with a bone evaluation in 2000–2004 and 65% in 2015–2020. Overall survival (OS) improved from 23 months in 2000–2004 to 33 months in 2015–2020. Inpatients with ER-positive and HER2-positive disease, the multivariable model showed improved survival by year of diagnosis, and further, patients with ER-negative/HER2-negative disease fared worse the first 2 years after diagnosis.  \nInterpretation: Our study delineates changes in the treatment and survival of pMBC over two decades. Stage migration, screening introduction, and changes in registration practice, however, prevent a valid assessment of a possible causal relationship.  \nARTICLE HISTORY  \nReceived 8 January 2024 Accepted 8 March 2024 Published 6 May 2024  \nKEYWORDS  \nBreast cancer; metastatic; epidemiology  \nIntroduction  \nApproximately 5–10% of annual breast cancer patients are diagnosed with synchronous distant metastases, primary metastatic breast cancer (pMBC), an essentially non-curative form of breast cancer mainly treated with palliative intentions and an expected median survival of 3–4 years with a difference between subtypes [1, 2] .  \nIn Denmark, the incidence of breast cancer increased monotonically among women up to 2010, where the rate of increase levelled off [3] . Several factors, however, are essential to understand stage-specific incidence and survival, including prevalence of screening, use of staging tests, classification, and  \ncoding of breast cancer. Firstly, population-based breast cancer screening for women aged 50 to 69 years, was ","cbCailSR4l1MYmSB","https://ap.wps.com/l/cbCailSR4l1MYmSB","pdf",1192386,11,"English","# Abstract\n# Background\n# Material and method\n# Results\n## Patient cohort and trends\n## Diagnostic practice changes\n## Survival outcomes\n# Interpretation\n# Introduction\n# Screening and staging background","[{\"question\":\"What was the study design and study period for primary metastatic breast cancer in Denmark?\",\"answer\":\"The study is a retrospective observational analysis of pMBC patients diagnosed between 2000 and 2020, including cases from all Danish oncology departments.\"},{\"question\":\"How did the number of primary metastatic breast cancer diagnoses change over time?\",\"answer\":\"From 2000–2004 to 2015–2020, diagnoses increased from 355 to 1,323, totaling 3,272 patients during 2000–2020.\"},{\"question\":\"What trends were found in survival and diagnostic/staging practices?\",\"answer\":\"Overall survival improved from 23 months (2000–2004) to 33 months (2015–2020), while diagnostic practices evolved, with a larger proportion evaluated using PET/CT or CT with bone evaluation by 2015–2020 compared with 2000–2004.\"}]","Incidence and survival of primary metastatic breast cancer in Denmark - implication of breast cancer screening, classification, and staging practice - study results and findings | PDF",1790043161,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e7198d0b442e29252bc16553ead5dc0.webp",983,1280,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12a402a1128ddfbe10907f9bdf5e4789.webp",982,1278,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8eccc6ad109b0bb011dc592bb724da00.webp",981,1277,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a98f2fcb4c5eb6aaf3bf0f3d4daa0ce2.webp",980,1276]